Key references: Short-acting bronchodilator therapy for COPD

  • Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008;149(6):380–90. https://www.ncbi.nlm.nih.gov/pubmed/18794557
  • Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD. Cardiovascular events associated with ipratropium bromide in COPD. Chest 2010;137(1):13–9. https://www.ncbi.nlm.nih.gov/pubmed/19363211
  • Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008;300(12):1439–50. https://www.ncbi.nlm.nih.gov/pubmed/18812535
  • Yang I, Dabscheck E, George J, Jenkins S, McDonald C, McDonald V, et al. The COPD-X Plan: Australian and New Zealand Guidelines for the management of chronic obstructive pulmonary disease 2020, Version 2.61. Milton, QLD: Lung Foundation Australia; February 2020. https://copdx.org.au/